Theodoros Dimitroulas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2568962/publications.pdf

Version: 2024-02-01

156 papers 2,711 citations

201385 27 h-index 264894 42 g-index

158 all docs

158 docs citations

158 times ranked 3600 citing authors

#	Article	IF	CITATIONS
1	Neuropathic pain in osteoarthritis: A review of pathophysiological mechanisms and implications for treatment. Seminars in Arthritis and Rheumatism, 2014, 44, 145-154.	1.6	157
2	Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World Journal of Gastroenterology, 2019, 25, 2162-2176.	1.4	122
3	Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. International Journal of Cardiology, 2016, 217, 135-148.	0.8	114
4	Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 748-751.	0.5	92
5	Symptom-based stratification of patients with primary Sj \tilde{A} ¶gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	2.2	76
6	The Role of Multimodality Imaging in the Evaluation of Takayasu Arteritis. Seminars in Arthritis and Rheumatism, 2013, 42, 401-412.	1.6	73
7	Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmunity Reviews, 2013, 12, 958-966.	2.5	72
8	Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Therapeutic Advances in Musculoskeletal Disease, 2016, 8, 86-101.	1.2	56
9	N-Terminal Pro-Brain Natriuretic Peptide Levels Are Elevated in Patients with Acute Ischemic Stroke. Angiology, 2005, 56, 723-730.	0.8	55
10	Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation. Arthritis Research and Therapy, 2017, 19, 32.	1.6	46
11	Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naìve patients with connective tissue diseases. International Journal of Cardiology, 2017, 236, 151-156.	0.8	45
12	Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology, 2008, 47, 1682-1685.	0.9	44
13	Early Detection of Cardiac Involvement in Systemic Sclerosis Assessed by Tissue-Doppler Echocardiography: Relationship with Neurohormonal Activation and Endothelial Dysfunction. Journal of Rheumatology, 2010, 37, 993-999.	1.0	44
14	The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis. Frontiers in Medicine, 2018, 5, 24.	1.2	43
15	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1013-1016.	0.5	43
16	Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). Rheumatology, 2020, 59, 1938-1948.	0.9	42
17	The role of nailfold capillaroscopy in the assessment of internal organ involvement in systemic sclerosis: A critical review. Autoimmunity Reviews, 2017, 16, 787-795.	2.5	39
18	A critical view on cardiovascular risk in systemic sclerosis. Rheumatology International, 2017, 37, 85-95.	1.5	38

#	Article	IF	Citations
19	Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatology International, 2011, 31, 263-267.	1.5	37
20	Asymmetric Dimethylarginine as a Surrogate Marker of Endothelial Dysfunction and Cardiovascular Risk in Patients with Systemic Rheumatic Diseases. International Journal of Molecular Sciences, 2012, 13, 12315-12335.	1.8	37
21	Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clinical Rheumatology, 2010, 29, 957-964.	1.0	35
22	Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease. Current Pharmaceutical Design, 2014, 20, 536-544.	0.9	35
23	Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis. Autoimmunity Reviews, 2012, 12, 305-312.	2.5	34
24	Heart involvement in rheumatoid arthritis: Multimodality imaging and the emerging role of cardiac magnetic resonance. Seminars in Arthritis and Rheumatism, 2013, 43, 314-324.	1.6	32
25	Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatology International, 2021, 41, 33-42.	1.5	32
26	Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology, 2015, 54, 1145-1152.	0.9	31
27	Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value. Diagnostics, 2019, 9, 220.	1.3	28
28	Primary Sjögren's Syndrome and Cardiovascular Disease. Current Vascular Pharmacology, 2020, 18, 447-454.	0.8	28
29	Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging. Inflammation and Allergy: Drug Targets, 2014, 13, 206-216.	1.8	28
30	Effects of Renin-Angiotensin System Inhibition on Left Atrial Function of Hypertensive Patients: An Echocardiographic Tissue Deformation Imaging Study. American Journal of Hypertension, 2010, 23, 556-561.	1.0	27
31	Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis. Nature Reviews Rheumatology, 2012, 8, 203-213.	3.5	27
32	Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2012, 30, 388-96.	0.4	27
33	Cardiac Tissue Characterization and Imaging in Autoimmune Rheumatic Diseases. JACC: Cardiovascular Imaging, 2017, 10, 1387-1396.	2.3	26
34	Complementary role of cardiovascular imaging and laboratory indices in early detection of cardiovascular disease in systemic lupus erythematosus. Lupus, 2017, 26, 227-236.	0.8	26
35	Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?. Current Rheumatology Reports, 2019, 21, 15.	2.1	26
36	Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. Clinical Biochemistry, 2012, 45, 1399-1403.	0.8	24

#	Article	IF	Citations
37	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Research and Therapy, 2018, 20, 267.	1.6	24
38	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome <i>vs</i> rheumatoid arthritis: a multicenter, case-control study. Rheumatology, 2021, 60, 170-178.	0.9	24
39	Natriuretic Peptides in Systemic Sclerosis-related Pulmonary Arterial Hypertension. Seminars in Arthritis and Rheumatism, 2010, 39, 278-284.	1.6	23
40	Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study. Rheumatology, 2017, 56, 1928-1938.	0.9	22
41	Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. Seminars in Arthritis and Rheumatism, 2021, 51, 137-143.	1.6	22
42	Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction. Journal of Inflammation Research, 2021, Volume 14, 1915-1931.	1.6	21
43	Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. International Journal of Cardiology, 2007, 121, 135-137.	0.8	20
44	N-Terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clinical Rheumatology, 2008, 27, 655-658.	1.0	20
45	Osteoarthritis pain has a significant neuropathic component: an exploratory in vivo patient model. Rheumatology International, 2014, 34, 315-320.	1.5	20
46	Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives. Rheumatology International, 2018, 38, 949-958.	1.5	20
47	Peripheral microangiopathyÂin precapillary pulmonary hypertension: a nailfold video capillaroscopy prospective study. Respiratory Research, 2021, 22, 27.	1.4	20
48	Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance. Inflammation and Allergy: Drug Targets, 2014, 13, 81-93.	1.8	20
49	Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance. Scandinavian Journal of Rheumatology, 2013, 42, 176-181.	0.6	19
50	Biologic drugs as analgesics for the management of osteoarthritis. Seminars in Arthritis and Rheumatism, 2017, 46, 687-691.	1.6	19
51	Comorbidity burden in systemic sclerosis: beyond disease-specific complications. Rheumatology International, 2019, 39, 1507-1517.	1.5	19
52	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. Arthritis Care and Research, 2017, 69, 1714-1723.	1.5	18
53	Novel insights into the role of inflammasomes in autoimmune and metabolic rheumatic diseases. Rheumatology International, 2018, 38, 1345-1354.	1.5	18
54	Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study. Arthritis Research and Therapy, 2019, 21, 253.	1.6	18

#	Article	IF	Citations
55	Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors. Clinical Rheumatology, 2013, 32, 1357-1364.	1.0	17
56	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. Hypertension Research, 2021, 44, 179-187.	1.5	17
57	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 1528.	1.0	17
58	Phenotyping Exercise Limitation in Systemic Sclerosis: The Use of Cardiopulmonary Exercise Testing. Respiration, 2016, 91, 115-123.	1.2	16
59	Mixedâ€Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary SjÁ¶gren's Syndrome Patients. Arthritis Care and Research, 2018, 70, 1064-1073.	1.5	15
60	Targeting very early systemic sclerosis: a case-based review. Rheumatology International, 2019, 39, 1961-1970.	1.5	15
61	Biologic Drugs as Analgesics for the Management of Low Back Pain and Sciatica. Pain Medicine, 2019, 20, 1678-1686.	0.9	15
62	Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis. Current Medicinal Chemistry, 2015, 22, 1943-1955.	1.2	15
63	Why Currently Used Diagnostic Techniques for Heart Failure in Rheumatoid Arthritis Are Not Enough: The Challenge of Cardiovascular Magnetic Resonance Imaging. Reviews in Cardiovascular Medicine, 2014, 15, 320-331.	0.5	15
64	Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores. Amino Acids, 2015, 47, 1995-2004.	1,2	14
65	Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. Atherosclerosis, 2014, 237, 38-44.	0.4	13
66	Associations between asymmetric dimethylarginine, homocysteine, and the methylenetetrahydrofolate reductase (<i>MTHFR</i>) C677T polymorphism (rs1801133) in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2016, 45, 267-273.	0.6	13
67	Cardiovascular magnetic resonance in the diagnosis and management of cardiac and vascular involvement in the systemic vasculitides. Current Opinion in Rheumatology, 2019, 31, 16-24.	2.0	13
68	Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets. Current Pharmaceutical Design, 2012, 18, 1457-1464.	0.9	13
69	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterranean Journal of Rheumatology, 2018, 29, 27-37.	0.3	13
70	B-type natriuretic peptide in rheumatic diseases: A cardiac biomarker or a sophisticated acute phase reactant?. Autoimmunity Reviews, 2012, 11, 837-843.	2.5	12
71	In vivomicrovascular and macrovascular endothelial function is not associated with circulating dimethylarginines in patients with rheumatoid arthritis: a prospective analysis of the DRACCO cohort. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 331-337.	0.6	12
72	Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases. Heart Failure Reviews, 2019, 24, 489-498.	1.7	12

#	Article	IF	Citations
73	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. Arthritis Research and Therapy, 2020, 22, 56.	1.6	12
74	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. Microcirculation, 2021, 28, e12665.	1.0	12
7 5	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. Clinical Rheumatology, 2021, 40, 4957-4968.	1.0	12
76	Edema and fibrosis imaging by cardiovascular magnetic resonance: How can the experience of Cardiology be best utilized in rheumatological practice?. Seminars in Arthritis and Rheumatism, 2014, 44, 76-85.	1.6	11
77	Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis. Rheumatology International, 2015, 35, 1913-1916.	1.5	11
78	Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatology International, 2018, 38, 161-167.	1.5	11
79	Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance. Inflammation and Allergy: Drug Targets, 2016, 14, 111-116.	1.8	11
80	Prospects of using cardiovascular magnetic resonance in the identification of arrhythmogenic substrate in autoimmune rheumatic diseases. Rheumatology International, 2018, 38, 1615-1621.	1.5	10
81	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093713.	1.2	10
82	Combined Brain-Heart Magnetic Resonance Imaging in Autoimmune Rheumatic Disease Patients with Cardiac Symptoms: Hypothesis Generating Insights from a Cross-Sectional Study. Journal of Clinical Medicine, 2020, 9, 447.	1.0	10
83	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. Rheumatology, 2021, 60, 5601-5609.	0.9	10
84	Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis. Rheumatology International, 2021, 41, 1045-1053.	1.5	10
85	The Double-Edged Sword of T1-Mapping in Systemic Sclerosisâ€"A Comparison with Infectious Myocarditis Using Cardiovascular Magnetic Resonance. Diagnostics, 2020, 10, 335.	1.3	9
86	Cardiovascular Magnetic Resonance Reveals Cardiac Pathophysiology in Autoimmune Rheumatic Diseases. Mediterranean Journal of Rheumatology, 2021, 31, 15.	0.3	9
87	Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis. International Journal of Cardiology, 2014, 172, 285-286.	0.8	8
88	Subclinical atherosclerosis in systemic sclerosis and rheumatoid arthritis: a comparative matched-cohort study. Rheumatology International, 2020, 40, 1997-2004.	1.5	8
89	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology, 2021, 60, 2223-2230.	0.9	8
90	Peripheral Microangiopathy in Patients with Precapillary Pulmonary Hypertension: Correlation with Cardiac Function and Patients' Functional Capacity. Study Design and Rationale. Mediterranean Journal of Rheumatology, 2020, 31, 369.	0.3	8

#	Article	IF	CITATIONS
91	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases. Journal of Inflammation Research, 2021, Volume 14, 6893-6906.	1.6	8
92	Biomarkers in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Current Vascular Pharmacology, 2011, 9, 213-219.	0.8	7
93	Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis. Frontiers in Medicine, 2017, 4, 89.	1.2	7
94	Adrenocorticotropic hormone: an effective "natural―biologic therapy for acute gout?. Rheumatology International, 2020, 40, 1941-1947.	1.5	7
95	Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients. Expert Review of Clinical Immunology, 2020, 16, 1105-1113.	1.3	7
96	Peripheral microangiopathy in Eisenmenger syndrome: A nailfold video capillaroscopy study. International Journal of Cardiology, 2021, 336, 54-59.	0.8	7
97	Genetic regulation of dimethylarginines and endothelial dysfunction in rheumatoid arthritis. Amino Acids, 2019, 51, 983-990.	1.2	6
98	Nailfold videocapillaroscopy: a novel possible surrogate marker for the evaluation of peripheral microangiopathy in pulmonary arterial hypertension. Scandinavian Journal of Rheumatology, 2021, 50, 85-94.	0.6	6
99	Cardiovascular Disease in the Systemic Vasculitides. Current Vascular Pharmacology, 2020, 18, 463-472.	0.8	6
100	Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus. Current Cardiology Reviews, 2020, 16, 178-186.	0.6	6
101	Scleroderma Renal Crisis Accompanied by New-Onset Pulmonary Hypertension: An Acute Systemic Endothelial Injury? Case Report and Literature Review. Inflammation and Allergy: Drug Targets, 2010, 9, 313-318.	1.8	6
102	Why currently used diagnostic techniques for heart failure in rheumatoid arthritis are not enough: the challenge of cardiovascular magnetic resonance imaging. Reviews in Cardiovascular Medicine, 2014, 15, 320-31.	0.5	6
103	Can we wean patients with inflammatory arthritis from biological therapies?. Autoimmunity Reviews, 2019, 18, 102399.	2.5	5
104	Nailfold videocapillaroscopic changes in patients with pulmonary arterial hypertension associated with connective tissue diseases. Rheumatology International, 2021, 41, 1289-1298.	1.5	5
105	Cardiovascular risk in systemic sclerosis: Micro- and Macro-vascular involvement. Indian Journal of Rheumatology, 2017, 12, 211.	0.2	5
106	N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. Rheumatology International, 2009, 29, 347-348.	1.5	4
107	Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study. Mediators of Inflammation, 2015, 2015, 1-8.	1.4	4
108	Genetic variations in the alanine–glyoxylate aminotransferase 2 (AGXT2) gene and dimethylarginines levels in rheumatoid arthritis. Amino Acids, 2017, 49, 1133-1141.	1.2	4

#	Article	IF	Citations
109	A case of sarcoidosisâ€associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-6.	0.8	4
110	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and nonâ€diabetic CKD. Journal of Clinical Hypertension, 2020, 22, 2239-2249.	1.0	4
111	Cardiovascular comorbidity in rheumatic and musculoskeletal diseases: Where we are and how can we move forward?. International Journal of Rheumatic Diseases, 2021, 24, 473-476.	0.9	4
112	Pulmonary Arterial Hypertension in Connective Tissue Disorders: The emerging role of screening and early diagnosis. A position paper for Greek Rheumatologists. Mediterranean Journal of Rheumatology, 2019, 30, 90-93.	0.3	4
113	Combined brain and heart magnetic resonance imaging in systemic vasculitides: fiction or real need?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 152-159.	0.4	4
114	Association Between Uric Acid and Worsening Peripheral Microangiopathy in Systemic Sclerosis. Frontiers in Medicine, 2021, 8, 806925.	1.2	4
115	Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review. Rheumatology International, 2022, 42, 1849-1854.	1.5	4
116	Limitations of the findings regarding the relationship between Nâ€ŧerminal pro–brain natriuretic peptide and systemic sclerosis–related pulmonary arterial hypertension: Comment on the article by Allanore et al. Arthritis and Rheumatism, 2008, 58, 2215-2216.	6.7	3
117	Clinical outcome of ultrasound-guided steroid injections for chronic shoulder pain. International Journal of Rheumatic Diseases, 2013, 16, 398-402.	0.9	3
118	Is There a Brain/Heart Interaction in Rheumatoid Arthritis and Seronegative Spondyloartropathies? A Combined Brain/Heart Magnetic Resonance Imaging Reveals the Answer. Current Rheumatology Reports, 2020, 22, 39.	2.1	3
119	Practical Issues in Managing Systemic Inflammatory Disorders During the COVID-19 Pandemic. Mediterranean Journal of Rheumatology, 2020, 31, 253.	0.3	3
120	Dickkopf-1 is downregulated early and universally in the skin of patients with systemic sclerosis despite normal circulating levels. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 45-49.	0.4	3
121	Humoral and cellular response to a third booster dose SARS-CoV- 2 vaccination in patients with autoimmune disease: a case series. Scandinavian Journal of Rheumatology, 2022, 51, 422-424.	0.6	3
122	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. Mediterranean Journal of Rheumatology, 2020, 31, 239.	0.3	2
123	Fever and temporal headache in a 70-year-old male with presumed large vessels vasculitis. Mediterranean Journal of Rheumatology, 2020, 31, 220.	0.3	2
124	Paget's disease of the vulva in a patient with scleroderma and underlying adenocarcinoma: case report. European Journal of Gynaecological Oncology (discontinued), 2009, 30, 458-9.	0.3	2
125	Current understanding and future perspectives of brain–heart–kidney axis in psoriatic arthritis. Rheumatology International, 2020, 40, 1361-1368.	1.5	1
126	Ventricular Tachycardia Has Mainly Non-Ischaemic Substrates in Patients with Autoimmune Rheumatic Diseases and a Preserved Ejection Fraction. Diagnostics, 2021, 11, 519.	1.3	1

#	Article	IF	Citations
127	AB1201â€INCREASING RATES OF INFLUENZA VACCINATION COVERAGE IN RHEUMATOID ARTHRITIS PATIENTS: DATA FROM A MULTICENTER, LONGITUDINAL COHORT STUDY OF 1,406 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1892.3-1892.	0.5	1
128	Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis. Mediterranean Journal of Rheumatology, 2020, 31, 230.	0.3	1
129	The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the â€~GO-UP' study. Quality of Life Research, 2022, 31, 1385-1399.	1.5	1
130	Lack of association between polymorphisms of thrombogenic genes and disease susceptibility in rheumatoid arthritis. Rheumatology International, 2013, 33, 2429-2432.	1.5	0
131	109.â€fUK Clinical Practice Use of Biologics in Monotherapy for the Treatment of Patients with Rheumatoid Arthritis. Rheumatology, 2014, 53, i99-i99.	0.9	0
132	Deciphering Cardiovascular Disease in Systemic Inflammatory Diseases Using Advanced Magnetic Resonance Imaging. Current Cardiovascular Imaging Reports, $2015, 8, 1$.	0.4	0
133	FRIO100â€The Role of Insulin Resistance and Inflammation on Symmetric Dimethylarginine in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 456.1-456.	0.5	0
134	THU0113â€Genetic Variations in The Alanine-Glyoxylate Aminotransferase-2 (AGXT-2) Gene Are Not Related To Levels of Dimethylarginines in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 220.2-220.	0.5	0
135	Risk factors for cardiovascular disease in rheumatoid arthritis. , 2017, , 39-52.		0
136	FRIO173â€Correlation between assymetric dimethylarginine and homocysteine levels in patients with rheumatoid arthritis. , 2017, , .		0
137	OP0092â€Decreased dickkopf-1 expression in clinically uninvolved skin from patients with systemic sclerosis. , 2018, , .		0
138	P175Diagnosing myocardial inflammation in systemic sclerosis and infective myocarditis: are the lake Louise criteria sufficient?. European Heart Journal Cardiovascular Imaging, 2019, 20, .	0.5	0
139	253Cardiovascular magnetic resonance pattern of acute cardiac events in systemic sclerosis. European Heart Journal Cardiovascular Imaging, 2019, 20, .	0.5	0
140	E071 $\hat{a} \in f$ Lack of association between nailfold capillary microscopic changes and cardiovascular risk in systemic sclerosis patients. Rheumatology, 2019, 58, .	0.9	0
141	AB0678â€ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WIT SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .	ΤΗ	O
142	OP0015â€INCIDENCE, RISK FACTORS AND VALIDATION OF THE RABBIT SCORE FOR SERIOUS INFECTIONS IN A REAL LIFE PROSPECTIVE STUDY OF PATIENTSWITH RHEUMATOID ARTHRITIS: DATA FROM 1.549 PATIENTS. , 2019, , .		0
143	SAT0247â€FEMALE SEX AND AGE AT DIAGNOSIS ARE ASSOCIATED WITH A DECREASED POSSIBILITY OF DRUG DISCONTINUATION IN GIANT CELL ARTERITIS: DATA FROM A MULTICENTER PROSPECTIVE COHORT OF 177 PATIENTS. , 2019, , .		0
144	P1012NAIL CAPILLARY DENSITY DURING POSTOCCLUSIVE REACTIVE HYPEREMIA AND VENOUS CONGESTION IS MORE IMPAIRED IN DIABETIC COMPARED TO NON-DIABETIC CKD PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0

#	Article	IF	CITATIONS
145	PO156SHORT-TERM BLOOD PRESSURE VARIABILITY IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD STAGE 2, 3A, 3B AND 4. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	O
146	Cardiovascular Risk in Systemic Sclerosis. Current Treatment Options in Rheumatology, 2020, 6, 282-298.	0.6	0
147	P628 Risk Factors Associated with Extraintestinal Manifestations in Patients with Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2021, 15, S566-S566.	0.6	O
148	AB0421 Low rates of retention of biologic dmard monotherapy in patients with rheumatoid arthritisin real life settings. , 2018, , .		0
149	THU0102â€High rates of residual disease activity despite current therapies in a real life rheumatoid arthritiscohort: data from 1096 patients. , 2018, , .		O
150	THU0427â€Comparable cardiovascular disease and neoplasm rates but higher frequency of depression in systemic sclerosis versus rheumatoid arthritis: a multicentre comparative study of comorbidities. , 2018, , .		0
151	Mediterranean Journal of Rheumatology December 2019 Highlights. Mediterranean Journal of Rheumatology, 2019, 30, 194.	0.3	O
152	FRIO493â€THE INTERLEUKIN-1B INHIBITOR CANAKINUMAB FOR REFRACTORY STILL'S DISEASE: LONG-TERM EXPERIENCE IN 50 CONSECUTIVE PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 845.1-845.	0.5	0
153	FRIO474â€IMMUNE CHECKPOINT INHIBITOR-INDUCED MUSCULOSKELETAL MANIFESTATIONS. A SYSTEMATIC REVIEW. Annals of the Rheumatic Diseases, 2020, 79, 834.1-834.	0.5	O
154	Mediterranean Journal of Rheumatology December 2018 Highlights. Mediterranean Journal of Rheumatology, 2018, 29, 182-183.	0.3	0
155	Arterial stiffness in rheumatoid arthritis: Current knowledge and future perspectivess. Indian Journal of Rheumatology, 2022, 17, 157.	0.2	O
156	How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed. European Journal of Case Reports in Internal Medicine, 0, , .	0.2	0